As an Oncomine Solutions customer, you are part of a global community which can benefit from:
Unparalleled Service and Support
Bespoke service and support, with a team on your side from new assay implementation through every-day testing.
Clinical Research Funding
Opportunities for investigator-initiated studies and education projects using next-generation sequencing with the Oncomine Clinical Research Grant Program.
Largest portfolio of end-to-end NGS solutions, from sample extraction to reporting, to fit your needs.
Keep scrolling to learn more about how becoming a member of the Oncomine Solutions Community means so much more than just using our products.
Explore the interactive map below (by clicking on the country flag icons)
to learn what our community is saying about their experiences with Oncomine Solutions.
Dr. Cecilia Yeung is a pathologist at the Fred Hutch Cancer Center (FHCC) with specialty training in hematopathology and molecular pathology. Her research focuses on understanding the clonal dynamics of myeloid malignancies with the goal of advancing precision oncology and expanding access to pathology services in low- and middle-income countries.
In collaborations with The Max Foundation and the National Cancer Institute, FHCC is helping to provide advanced molecular diagnostics to patients in underserved populations and accelerate therapeutic developments for myeloid neoplasms through exciting new clinical trials.
The program, established in 2019, is called the Spot on CML Collaboration. As part of this clinical trial, physicians in LMICs are able to draw blood samples and place four drops on test cards that are then mailed and transferred to the lab at Fred Hutch for processing.
Upon receiving the results, the Max Foundation informs the physician of diagnosis and helps to inform appropriate treatment. The lab at Fred Hutch leverages the amplicon-based NGS, a technique Dr. Yeung says has performed remarkably well, even with challenging samples that contain very limited amounts of nucleic acid. Since the program started, the molecular oncology lab at FHCC has processed nearly 1000 samples from 23 countries.
As part of their clinical research, the molecular oncology lab at FHCC evaluated the Oncomine™ Myeloid Assay GX on the Genexus™ System. The assay was selected because of its ability to rapidly detect both RNA fusions and DNA variants in the same sequencing run and produce harmonized data across sister labs.
Dr. Yeung concluded that the Genexus™ System and Oncomine™ Myeloid Assay GX demonstrated strong performance with challenging samples and that they have the potential to make a significant impact on global oncology.
Through their continued collaboration, Dr. Yeung, the molecular oncology lab at FHCC, and The Max Foundation are helping to advance the future of precision oncology in low and middle-income countries.
Cecilia Yeung, MD.
Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center
Medical Director, Fred Hutch CLIA Laboratories
Thermo Fisher Scientific is dedicated to providing exceptional products and services to our customers. As an Oncomine Solutions user, you have access to a worldwide team committed to enabling NGS testing to a broad spectrum of oncology research labs.
With a team on your side for everything from new assay implementation through every-day testing, we are here to support you and your laboratory. Learn more about Service and Support for Oncomine Solutions customers.
We understand the value of supporting independent research projects in order to promote excellence in molecular diagnostics. The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects, on molecular profiling in oncology, with the goal to increase high quality molecular profiling and to help democratize the future of precision medicine.
We welcome applications from laboratories of any size across all continents.*
“In the long term, our goal is to promote equity of access to molecular profiling in cancer research and further democratize the future of precision medicine.”
Dr. José Luís Costa
Program Director, Oncomine Clinical Research Grant, Thermo Fisher Scientific
Gain more detail insights faster with Oncomine's complete end-to-end NGS workflow solution. With a broad assay menu across key applications, and the smallest sample input requirements in the industry, this means you can analyze more samples and produce complete bioinformatic reports that drive key insights. As a partner, we are able to support you every step of the way.
Each year, we attend dozens of scientific conferences and events, host webinars and virtual meetings, and bring our Oncomine Solutions Community members together for user meetings in all corners of the globe. See all of the upcoming opportunities to connect with us here.
> View Events
Join Our e-Newsletter
Sign up for our e-newsletter to stay up-to-date on the latest Oncomine Solutions news, including new product announcements, educational resources, and opportunities to connect with us via webinars and scientific events.
Our R&D and product development teams will come to you.
Submit your questions to this form below. Our experts will review and respond, and you’ll have the chance to have your Q&A featured here and in our e-newsletter (anonymously) to promote knowledge-sharing among our Oncomine Solutions Community!
For Research Use Only. Not for use in diagnostic procedures.
* Except where prohibited, licensed, or restricted by federal, state, provincial, or local laws, regulations, or agency/institutional policy.